Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

BMC Psychiatry, Год журнала: 2020, Номер 20(1)

Опубликована: Янв. 16, 2020

Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. been reported have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, intractable childhood epilepsy. Yet its application the field of psychiatry is lesser known.The first clinically-focused systematic review on emerging medical across all major psychiatric disorders was conducted. Current evidence regarding whole plant formulations plant-derived cannabinoid isolates mood, anxiety, sleep, psychotic deficit/hyperactivity disorder (ADHD) discussed; while also detailing clinical prescription considerations (including pharmacogenomics), occupational public health elements, future recommendations. The literature conducted during 2019, assessing data from case studies trials involving medicinal or for (neurological conditions pain were omitted).The present therapeutics nascent, thereby it currently premature recommend cannabinoid-based interventions. Isolated positive have, however, revealed tentative support cannabinoids (namely cannabidiol; CBD) social anxiety; with mixed (mainly positive) adjunctive use schizophrenia. Case suggest that may be beneficial improving sleep post-traumatic stress disorder, however weak. Preliminary findings indicate no benefit depression high delta-9 tetrahydrocannabinol (THC) therapeutics, CBD mania. One isolated study indicates some an oral cannabinoid/terpene combination ADHD. Clinical prescriptive consideration involves caution high-THC (avoidance youth, people anxiety disorders), gradual titration, regular assessment, cardiovascular respiratory disorders, pregnancy breast-feeding.There encouraging, albeit embryonic, treatment a range disorders. Supportive are key isolates, clinicians need mindful safety considerations, especially if initiating higher dose THC formulas.

Язык: Английский

---

Changing landscape of cannabis: novel products, formulations, and methods of administration

Current Opinion in Psychology, Год журнала: 2019, Номер 30, С. 98 - 102

Опубликована: Апрель 9, 2019

Язык: Английский

---

Diversity of molecular targets and signaling pathways for CBD

Pharmacology Research & Perspectives, Год журнала: 2020, Номер 8(6)

Опубликована: Ноя. 9, 2020

Abstract Cannabidiol (CBD) is the second most abundant component of Cannabis plant and known to have effects distinct from Δ 9 ‐tetrahydrocannabinol (THC). Many studies that examined behavioral CBD concluded it lacks psychotomimetic attributed THC. However, was shown a broad spectrum on several conditions such as anxiety, inflammation, neuropathic pain, epilepsy. It currently thought engages different targets hence CBD’s are be due multiple molecular mechanisms action. A well‐accepted set include GPCRs ion channels, with serotonin 5‐HT 1A receptor transient potential cation channel TRPV1 being two main targets. has also been target G protein‐coupled receptors (GPCRs) cannabinoid opioid receptors. Other suggested role for additional channels CBD. Currently, clinical efficacy not completely understood. Evidence derived randomized trials, in vitro vivo models real‐world observations support use drug treatment option neuropathy, many other conditions. Hence an understanding current status field relates great interest so, this review, we findings recent highlight these

Язык: Английский

---

Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals

Molecules, Год журнала: 2020, Номер 25(18), С. 4078 - 4078

Опубликована: Сен. 7, 2020

Industrial hemp (

Язык: Английский

---

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis

Social Science & Medicine, Год журнала: 2019, Номер 233, С. 181 - 192

Опубликована: Июнь 8, 2019

Язык: Английский

---

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Basic & Clinical Pharmacology & Toxicology, Год журнала: 2022, Номер 130(4), С. 439 - 456

Опубликована: Янв. 27, 2022

Cannabidiol (CBD) is an abundant non-psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), 2 (CB2), GPR55, transient potential vanilloid (TRPV) and peroxisome proliferator-activated gamma (PPARγ). By modulating the activities these CBD exhibits multiple therapeutic effects, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, analgesic anticancer properties. could also be applied to treat or prevent COVID-19 its complications. Here, we provide narrative review CBD's applications human diseases: from mechanism action clinical trials.

Язык: Английский

---

The “Entourage Effect”: Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders

Current Neuropharmacology, Год журнала: 2019, Номер 18(2), С. 87 - 96

Опубликована: Сен. 4, 2019

Mood disorders are the most prevalent mental conditions encountered in psychiatric practice. Numerous patients suffering from mood present with treatment-resistant forms of depression, co-morbid anxiety, other and bipolar disorders. Standardized essential oils (such as that Lavender officinalis) have been shown to exert clinical efficacy treating anxiety As endocannabinoids suggested play an important role major generalized disorders, Cannabis sativa was for their treatment. The endocannabinoid system is widely distributed throughout body including brain, modulating many functions. It involved related its activity may be modified by exogenous cannabinoids. CB1 CB2 receptors primarily serve binding sites well phytocannabinoids, produced cannabis inflorescences. However, ‘cannabis’ not a single compound product but known complicated molecular profile, producing plethora phytocannabinoids alongside vast array terpenes. Thus, “entourage effect” positive contribution derived addition terpenes Here, we review literature on effects cannabinoids discuss possibility enhancing cannabinoid symptoms terpenoids. Possible underlying mechanisms anti-depressant anxiolytic reviewed. These natural products potential source new medications treatment

Язык: Английский

---

Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)

Current Neuropharmacology, Год журнала: 2018, Номер 17(8), С. 710 - 736

Опубликована: Авг. 27, 2018

Background: Obsessive-compulsive disorder (OCD) is associated with affective and cognitive symptoms causing personal distress reduced global functioning. These have considerable societal costs due to healthcare service utilization. Objective: Our aim was assess the efficacy of pharmacological interventions in OCD clinical guidelines, providing a comprehensive overview this field. Methods: We searched PubMed database for papers dealing drug treatment OCD, specific focus on treatments antidepressants, antipsychotics, mood stabilizers, off-label medications, pharmacogenomics. Results: Prolonged administration selective serotonin reuptake inhibitors (SSRIs) most effective. Better results can be obtained SSRI combined behavioral therapy (CBT) or similarly oriented exposure response prevention (ERP). Refractory could treated different strategies, including switch another clomipramine, augmentation an atypical antipsychotic. The addition medications other than antipsychotics intravenous antidepressant needs further investigation, as evidence inconsistent. Pharmacogenomics personalization reduce resistance. Conclusion: SSRI/clomipramine combination CBT/ERP optimal compared each alone treatments. New strategies refractory are needed. role pharmacogenomics become preponderant coming years.

Язык: Английский

---

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders

Frontiers in Psychology, Год журнала: 2019, Номер 10

Опубликована: Ноя. 8, 2019

Accumulated evidence indicates that cannabidiol (CBD), a nonpsychotomimetic and nonaddictive main component of the Cannabis sativa plant, reverses anxiety-like behavior. The purpose present study was to assess efficacy CBD treatment for Japanese late teenagers with social anxiety disorder (SAD). Thirty-seven 18-19-year-old SAD avoidant personality received, in double-blind study, cannabis oil (n = 17) containing 300 mg or placebo 20) daily 4 weeks. symptoms were measured at beginning end period using Fear Negative Evaluation Questionnaire Liebowitz Social Anxiety Scale. significantly decreased by both scales. results indicate could be useful option treat anxiety.

Язык: Английский

---

Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies

Pain, Год журнала: 2021, Номер 162(1), С. S5 - S25

Опубликована: Март 15, 2021

This narrative review represents an output from the International Association for Study of Pain's global task force on use cannabis, cannabinoids, and cannabis-based medicines pain management, informed by our companion systematic meta-analysis preclinical studies in this area. Our aims are (1) to describe value studying cannabinoids endogenous cannabinoid (endocannabinoid) system modulators preclinical/animal models pain; (2) discuss both pain-related efficacy additional pain-relevant effects (adverse beneficial) endocannabinoid as they pertain animal pathological or injury-related persistent (3) identify important directions future research. In service these goals, provides overview pharmacology modulators, with specific relevance describes pharmacokinetics rodents humans; highlights differences discrepancies between clinical Preclinical (rodent) have advanced understanding underlying sites mechanisms action suppressing nociceptive signaling behaviors. We conclude that substantial evidence supports contention hold considerable promise analgesic drug development, although challenge translating knowledge into clinically useful is not be underestimated.

Язык: Английский

---